Carbamazepine (All indications) - Medication and Pregnancy KB

Carbamazepine (All indications) updated on 04-22-2025

Caesarean

R analysis

id	Study	Lib. in paper	Exposition period	Study type All studies Case control excluded Only case control	Control type	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S18699 R79533	Mazzone (Carbamazepine) (Controls exposed to LTG) (Mixed indications), 2025	Cesarean section	during pregnancy (anytime or not specified)	population based cohort retrospective	exposed to other treatment, sick excluded	Adjustment: No	0.84 [0.69;1.04] ^C excluded (control group)	175/600 482/1,469	657	600		ref
S18700 R79541	Mazzone (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2025	Cesarean section	during pregnancy (anytime or not specified)	population based cohort retrospective	unexposed (general population or NOS)	Adjustment: Yes	0.98 [0.75;1.28]	175/600 186,309/624,794	186,484	600		ref
S9598 R33995	Artama (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013	Caesarean section	during pregnancy (anytime or not specified)	population based cohort retrospective	exposed to other treatment, sick excluded	Adjustment: No	0.94 [0.62;1.43] ^C excluded (control group)	191/1,084 32/173	223	1,084		ref
S9599 R34007	Artama (Carbamazepine) (Controls unexposed, disease free), 2013	Caesarean section	during pregnancy (anytime or not specified)	population based cohort retrospective	unexposed, disease free excluded	Adjustment: Yes	1.16 [0.99;1.36] excluded (control group)	191/1,084 114,791/721,948	114,982	1,084		ref
S9600 R34019	Artama (Carbamazepine) (Controls unexposed, sick), 2013	Caesarean section	during pregnancy (anytime or not specified)	population based cohort retrospective	unexposed, sick	Adjustment: Yes	0.95 [0.78;1.17]	191/1,084 331/1,800	522	1,084		ref
S9751 R34815	Borthen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010	Caesarean	during pregnancy (anytime or not specified)	population based cohort retrospective	exposed to other treatment, sick excluded	Adjustment: No	1.13 [0.75;1.71] ^C excluded (control group)	81/388 44/233	125	388		ref
S9753 R34823	Borthen (Carbamazepine) (Controls unexposed, disease free), 2010	Caesarean	during pregnancy (anytime or not specified)	population based cohort retrospective	unexposed, disease free excluded	Adjustment: Yes	1.50 [1.20;1.90] excluded (control group)	81/388 51,806/362,302	51,887	388		ref
S9755 R34831	Borthen (Carbamazepine) (Controls unexposed, sick), 2010	Caesarean	during pregnancy (anytime or not specified)	population based cohort retrospective	unexposed, sick	Adjustment: No	1.19 [0.91;1.57] ^C	81/388 337/1,863	418	388		ref
S9615 R34164	Endo (Carbamazepine) (Controls unexposed, disease free), 2004	Cesarean section	throughout pregnancy	retrospective cohort	unexposed, disease free excluded	Adjustment: No	7.86 [1.93;32.11] ^C excluded (control group)	4/8 74/656	78	8		ref
S9616 R34179	Endo (Carbamazepine) (Controls unexposed, sick), 2004	Cesarean section	throughout pregnancy	retrospective cohort	unexposed, sick	Adjustment: No	1.29 [0.02;82.50] ^C	4/8 0/1	4	8		ref
					Total	4 studies	1.02 [0.89;1.17]		187,428	2,080
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; ^C: calculated odds ratio from numbers of events and effectives

Forest plot

1: Carbamazepine) (Controls unexposed, NOS) (Mixed indications; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Controls unexposed, sick; 4: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

Publication bias and p-hacking diagnosis

funnel plot

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Sub-groups analysis using all included studies

excluded 9615, 9751, 9753, 9598, 9599, 18699